ALNYLAM PHARMACEUTICALS, INCALNYLAM PHARMACEUTICALS, INCALNYLAM PHARMACEUTICALS, INC

ALNYLAM PHARMACEUTICALS, INC

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−18.50MXN
Revenue estimate
‪7.09 B‬MXN
Market capitalization
‪311.77 B‬MXN
−60.04MXN
‪−7.48 B‬MXN
‪31.05 B‬MXN
‪125.76 M‬
Beta (1Y)
1.26

About Alnylam Pharmaceuticals, Inc.

CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Employees (FY)
‪2.1 K‬
Founded
2002
FIGI
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where ALNY is featured.

Frequently Asked Questions

The current price of ALNY is 2507.55 MXN — it has increased by 2.63% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ALNYLAM PHARMACEUTICALS, INC stocks are traded under the ticker ALNY.
ALNYLAM PHARMACEUTICALS, INC is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
ALNY stock is 2.61% volatile and has beta coefficient of 1.26. Check out the list of the most volatile stocks — is ALNYLAM PHARMACEUTICALS, INC there?
ALNY earnings for the last quarter are 20.05 MXN per share, whereas the estimation was −25.20 MXN resulting in a 179.55% surprise. The estimated earnings for the next quarter are −20.15 MXN per share. See more details about ALNYLAM PHARMACEUTICALS, INC earnings.
ALNYLAM PHARMACEUTICALS, INC revenue for the last quarter amounts to ‪13.08 B‬ MXN despite the estimated figure of ‪6.92 B‬ MXN. In the next quarter revenue is expected to reach ‪7.42 B‬ MXN.
Yes, you can track ALNYLAM PHARMACEUTICALS, INC financials in yearly and quarterly reports right on TradingView.
ALNY stock has risen by 2.03% compared to the previous week, the month change is a 2.03% rise, over the last year ALNYLAM PHARMACEUTICALS, INC has showed a 23.82% decrease.
ALNY net income for the last quarter is ‪−2.34 B‬ MXN, while the quarter before that showed ‪2.58 B‬ MXN of net income which accounts for −190.93% change. Track more ALNYLAM PHARMACEUTICALS, INC financial stats to get the full picture.
Today ALNYLAM PHARMACEUTICALS, INC has the market capitalization of ‪311.77 B‬, it has decreased by 3.32% over the last week.
No, ALNY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALNY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACEUTICALS, INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has ‪2.10 K‬ employees. See our rating of the largest employees — is ALNYLAM PHARMACEUTICALS, INC on this list?
We've gathered analysts' opinions on ALNYLAM PHARMACEUTICALS, INC future price: according to them, ALNY price has a max estimate of 6795.58 MXN and a min estimate of 2339.74 MXN. Read a more detailed ALNYLAM PHARMACEUTICALS, INC forecast: see what analysts think of ALNYLAM PHARMACEUTICALS, INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACEUTICALS, INC EBITDA is ‪−3.87 B‬ MXN, and current EBITDA margin is −12.48%. See more stats in ALNYLAM PHARMACEUTICALS, INC financial statements.